20th Mar 2014 07:57
LONDON (Alliance News) - GlaxoSmithKline PLC Thursday said that a late stage trial of its MAGE-A3 cancer immunotherapeutic for patients with non-small-cell lung cancer did not meet two of its co-primary endpoints, as it failed to extend disease-free survival compared to a placebo.
It did not extend disease-free survival in the overall group of patients who were MAGE-A3 positive, meaning those who have a tumour-specific antigen that is present in a variety of cancers but not in normal cells, the trial's first co-primary endpoint. It also did not extend disease-free survival in MAGE-A3 positive patients who did not receive chemotherapy, the second co-primary endpoint.
However, Glaxo will continue the trial to assess the third co-primary endpoint, which will assess if a subset of MAGE-A3 positive patients may benefit from the treatment with the immunotherapeutic. It expects results from this analysis in 2015.
It said it currently remains blinded to the overall trial data that has been analysed for the first two co-primary endpoints, to allow it to assess the third endpoint without bias.
The Independent Data Monitoring Committee had raised no specific concern for the continuation of the trial, and said that it was in line with the known safety information for the immunotherapeutic.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline